Immune checkpoint inhibitor refractory colitis leading to total colectomy in a melanoma patient.
(2023) Acta Gastro-Enterologica Belgica — Vol. 86, n° 2, p. 371-373 (2023)
Files
2023_Baczewska_Acta_Gastroenterol_Belg.pdf
Open Access - Adobe PDF
- 661.87 KB
Details
- Authors
- Abstract
- Immunotherapy is becoming more and more relevant in the treatment of advanced melanoma. Proper management of its side effects can prevent severe complications. We describe the case of a 73-year-old patient with severe refractory colitis secondary to immunotherapy. The patient has been treated for 6 months with Nivolumab, an anti-PD-1, as adjuvant therapy for locally advanced melanoma. He was admitted to the hospital with a deteriorating general condition associated with severe diarrhea and rectal bleeding for 3 weeks. Despite three lines of treatment (high dose corticosteroids, infliximab, mycophenolate mofetil), the patient still presented clinical and endoscopic colitis, with additional infectious complications. The patient required surgical management for total colectomy. In this article we present one of the rare cases of autoimmune colitis that did not respond to various immunosuppressive treatments and required surgery.
- Affiliations
Citations
Baczewska, N., Philippart, M., Siplet, J., Baurain, J.-F., Stainier, L., Laterre, E., Duck, L., & Coche, J.-C. (2023). Immune checkpoint inhibitor refractory colitis leading to total colectomy in a melanoma patient. Acta Gastro-Enterologica Belgica, 86(2), 371-373. https://doi.org/10.51821/86.2.10400 (Original work published 2023)